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Abstract
A retrospectIve review of 200 patients with acute
coronarysyndrome4CSiand chronic kidneydisease
(CKO( was compared to 200 patients without CKD to
investigate the incidence ofbieedthg. Logistic reQres
son ana/y5is inentirted CKD as an independent risk
.hactor for hieeaiho (OR 1.82, 950 011.02 3.25).
3750 catenrs v/In ALISavcear 7u .‘:ave cw
Introduction
There are appmximatelr St )0.( )( 10 people o ith end
stape renal disease (ESRD) and 2 million with chronic
kidney disease (CKD) in the United States.’ horty
one percent of patients with ESRD will succumb to
cardiovascular disease’ and moje than one in live of
these deaths will he as a result ol’an acute mvocardial
inlaretionu The inierioroutcornes of patients with end
sta5e renal disease lollowing ntrocardial nlarctions
have been attributed to a vanetv of causes includine
higher prevalence of cornorbidities in patients ‘ ith
renal dseasc. certain vascular charaoeristcs, heher
leads of honioc steine and differences in manage—
rnent371’5 These differences in management include
less frequent beta-blocker or aspirin therapo less
utilization of thromholvtics and infrequent percuta
neous revascularization procedures in patients with
acute mvocardiil infarctions and CKD compared to
patents with normal kidnen unction.
\ledical thumpu br acute ronara s\ ndrome
ACS) hcauil relies on anticoaguiant and anti
platelet therapy.’ However, due to fear of bleeding
complications secondar3 to urernic plate let du sf3 nc
finn. patients with CKI) commonly do not recede
these. blood thinning agen.ts. although differences in
bleeding eon.ep1icaton.s un patien.ts presentIng with
.ACS wit.li. or without CKD i..ave never been e:vaiuated
outsid.eaost—hoc ana’l.vsisofa randomize.d control led
inns. ttie of oiirtudr wa tocvaluatc thu Inn,
dunce of’bieedinu coinplication in patierit admitted
oh ACS and UK H.
Methods
After approval by the appropriate instittitional review
hoards. an analysis of computerized discharge diagno
sis was pertormed at two major hospitals in Honolulu.
Hawaii. from January 2000 until June 2003. Patients
earrr inst art ICDO code for acute coronar\ syndrome
and chronic kidner disease as primair or secondary
diagnosis were included. Patients ‘a ith a creatininc
of less then I .5 mg.’dI on admission were excluded
from the analr ‘ds. The second group of patients with
acute coronary syndromes without UK F) was identi
tied during the same period of time. In both groups.
patients with acute renal failure were excluded from
analysis.
Demographic and clinical data were extracted m
specified in the results section. Bleednin was defined
as either rn inoror major hleedino episode ti.iI low ins the
TIMIbleedinsrcriteria.’ We catestorized particIpants
into two sroups based on the existence nt chronic
kidney disease. Normally distributed data reported
as mean and standard de\ iation (SD). Characteristics
between the two groups were compared by Chi-Square
for dichotomous variables and Mann—Whitney U lAst
and Student’s T—test for continuous variables. To deter
mine the independent association between incidence of
bleeding and other cofactors including CKD we used
r)rnar\ locistle rcercsIon analysis to LntcnilJte ouds
ratios.
-\lpha—lcvel wa set at 0.05. unless otherwise
ctated Statistical analu cs \acre ocrbormed with thy
use of SPSS a ersiori It if rChcauo. IL.
Results
Baseline Characteristics
We. ide.n.tified.20( patients with and 200 petients wAS—
out UK H admitted for ..\CS, Patie.nts with ekd. were
older then those without (7K1) (69 a 13.3 vs 66,5 ±
3.7 cars. p=O.O) 01 able if. P,itients in the CK1)
were ni me ikelv to he female and n n-CaLicasian.
and l’ia d no we di ahetc s, ha nertei’ision ous history
of niroc.’dicl inlarcton, cerebral aascs,lrtr dseasc.
so:.. ro. .‘ .:. OvE/MBr1/ soon
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peripheral vascular disease. congestive heart failure.
and atrial fibrillation (Table 2). On admission. patients
with CKD more cummonlv presented with acute heart
failure, more frequently ss crc anemic and had a higher
activated partial thromboplastin time (PiT) compared
to patients without CKD Tables I and 3).
Incidence of Bleeding
There s as a trend towards more el inicali os crt bleed
ing in patients ss ith CKD than in patients s ith normal
kidney function (27.5% vs 20.5%,p=0. 1(31) (Table 4).
Patients with CKD more frequently received blood
transfusions compared to patients admitted \vithACS
without coexisting renal disease mean I .3 ± 3.03 vs
0i3 ± 2.98. p=O. 11 8).
In binary logistic analysis CR1) was associated
with the occurrence of any kind of bleeding compli
cation (OR 1,82. 95% Cl 1.02 to 3.25, p=0.042), as
was coronary angiograph\ (OR 3.44. 95% CI I $7
to 6.34. p<O.000 U after exclusion of patients who
underwent coronary arter by pass grafting (Figure St.
Use of Clopidogrel (OR 0.39. 95% Cl 0.22 to 0.69)
and higher platelet counts (OR 0,98. 95% Cl 0,98 to
0.99) were associated with less frequent bleeding.
Therapeutic Interventioiis
Aspirin. Clopidogrel. GPlIbllIa—lnhihitors. Enoxapa—
rin, and IV heparin were less frequently administered
toCKD patients (Figure I). Patients with CKD also did
notreceive as much invasive therapy, with less frequent
utilization of diagnostic angiography procedures and
percutaneous eoronar interventions (Figure 2).
Discussion
This study suggests that patients with chronic renal
failure are more at risk for bleeding than those with
out chronic renal failure. Although we documented a
higher incidence of bleeding (27.5 vs 20.5%). and
more frequent transfusions in the (‘KD patients, this
was not found to he statistically significant (p=0. I () I).
In logistic regression analysis, after accounting for
anti—platelet agents. aspirin. age. and other confound
ing factors. we faund that CKD s as associated with
the combined outcome of major and minor bleeding.
independent of the sex erity of renal dysfunction.
The conflicting results are likely a result of the small
number of patients in our initial analysis and this is
one of the limitations 01 our study.
Although one might expect loss er bleeding rates
with less anti-coagulant therapy. ‘ s e saw a
higher incidence of bleeding. This may he second
ary to uremic platelet dysfunction and other, as yet
unspecilied factors.
All types of anti—coagulation and therapeutic
interventions ssere documented as less trequentl
emploed in CKD patients. It is likely that the pre
Table 2.— Comorbid conditions
CKD (n=200Y Non-CKDIn=200)
- j P-value
DM using insuhn 28% 8% <0.0001
DM not using insulin 19% 16% 0.372
Hypertension’ 88% 63% <0.0001
Hyperlipidemia 40% 42% 0.729
AMI 41% 14% <0.0001
OVA 23% 6% <0.0001
PVD 14% 2% <0.0001
CHF 37% 3.5% <0.0001
Atib 15% 4.5% <0.0001
CKD defined as a Creatinine of 44.5 rng!dl
Defined as history of diabetes. regardless of duraSon of disease, need for antidiabeyc agents. or a fasting
ood sugar > m. mol or 126 mg dl
Defined as BP> 14090 on 2 separafe occasions
:1cip den’ d aonc edo ap ic ‘- lb cta o Dls72’fl d LL “ tS <“3 9 O o”<
artery daease, or HDL less than 40
CKD (n44001 Non-CKD n=200i P-value
Femae 48%
Age 69 ± 13.3 66.5 ± 13. 0.079
Ethnci:v
29%
Asian
j <0.0001
Pacific Islander
DC,,
Caucasian
24%
44.5%
Otner
0.004
16%
13%
Table 1 .— Baseline Characteristics
KiIIip Class< 0.0002
Class I 58% 85%
Class II 36%
Class III 20% 2%
Class IV 7% 1%
Medicare Insurance
C
34%
85%
32% <0.0001
* demonstrating no evidence of heart failure in Class I. mild-mod CHF in Class II. overt pulmonary edema in
Class Ill and cardiogenic shock in Class IV 21)
CKD dehned as a Creatinne of <1.5mg d
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sumed risk of bleeding complications in this group
is what motivated the lack of medical interventions.
Ho ever, this has never been adequatel\ researched
as CKD patients are frequently excluded from studies
on anti—coagulant therapy. There are no guidelines
for the use of GPlIb/lIIa inhibitors in patients with
CKD and onl recentl has dosing information of
los —molecular weight heparin in CKD patients been
released. Recent studiesdemonstrate mixed results on
the use of anti-coagulant therapy in this group Two
studies utilizing the GPilh lila inhibitor. abci simab
in patients with CXI) during PCI tail to demonstrate
an increased risk otrnajorhleedmg. sin the ESPRIT
trial sub-group analysis, which examined the effects
of the GPIIb/ll In inhibitoreptifihatide in patients with
chronic kidne disease undercoing coronary artery
stent placement. patients w dli CX D were found to he
more at risk for bleeding) However, in these studies
there are limitations that pres ent the application of
these results to a large number of patients. includinc
small sample sizes, problems with post-hoc analysis
and lack of generalizahility of the study populations
Freeman’s studs on the use of GPilhfllla inhibitors in
CXI) patients presentinc with ACS found a tss n—fold
increase in major bleeding e ems thai appeared to
correlate with decreasing creatinine clearance, The
implications of his findings of increased bleeding.
which are similar to those here arc unclear, as lie also
notes that the use of 0 Pith lila inhibitors offered a
significant protective effiet in decreased mortality.
Our observation of increased bleeding events in
patients ith C K[) sienifies the need fdr further pro
spective trials to clarif the risk of bleeding in patients
with CXI) being treated for ACS,
In addition to uremic platelet dysfunction. the
observation of i nereaseu bleeding in patients with
CXI) treated with anticoagnlants ma he c\plalncd by
alteration of the pharmacokrnctics of anticoagulants in
renal insufficiency. The pharmacokinetics of GP11h/
lIla inhibitors and loss molecular wciht hepanins arc
altered in those ss oh renal in’ufnicicncv. It is pos
sihlc that inadequate dose adjustment may partially
account for the increased association with bleeding
in ihose patients in horn they were utilited. In the
future. optimal dosing of antieoayulann— Idlloss inc
acute coronary syndrome in the setting of renal failure
needs to he determined.
Our stud\ populttn was ethnically diserse. ith
Caucasians accounting tor only a injnonit\ of the pa
tients examined as compared to other studies, ss hieh
have been done largely on Caucasian and African—
American populHions. It is. unclear whai ellect ethnic
backv mu nd may have had In our data.
The design of the study as a retrospective chart
review is also limiting in that we can only note as
socutnoils. In order to reall estahlih hether there
N H significant role bin uremia iii bleedinc. we ss ould
Taole 4
— Bleeorg Comphicauons
JCKD n=200 Non-CKD ln=200’ J P-value
docLZnled27S 20.5 01
#of PRECs trarsfused 3 :3Q3 033 .2.98 0 118
CKD defined as a Creasmne of 1 .5 ma 0
Aspirin Ciopidogret iv.: heparin Enoxapartn SPiiBifla
ZCKD Einon-CKDI
F L,re —— Art coagc ant Therapy Used r Patents Admitted for Ac:jte Coron
Syrdm”ie
[CKi. rt non-CKD
CABG
F gure 2 — Irvasive Treatments Ut mzed n Management f Acute Co orary Svr’drome
Patients
34€
need to have a prospective trial. It also hinders us in
Conclusions
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our evaluation of long-term consequences for bleed-
Pat ients with chronic kidney disease routinely receinc
less anticoagulantand anti—platelet treatment foracute
coronary syndrome partly out of concern for bleeding
complications. Given that CK[) might he a rick factor
for bleeding complications. appropriate manage
ment ctratcrne must he invcstjealcd. Randomi,ed
controlled trials are needed to establish the role of
uremic platelet dysfunction in bleeding complica
tions and to determine the s afetv of anti—platelet and
anti—coaculant medications.
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Figure 3.— Logistic Regression Analysis of Bleeding Incidence
Corfounders entered n logistic regression model: Aspirin, Plavix. GP2B3A. Enonaparin. Heparin. age. duraton
kidney d:sease. coumadin prior to admission, any oath done. INR max. PTT man. PCI done.
CKD defined as a Creatin.ine of wI .5 mgdl. PCI is percutaneous intervention. CI confidence interval. Data is
plotted as odds ratio with error bars sflowing 95% confidence interval. Error bars to the right sine of the dashed
line favor association, those to the left, favor no association.
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